v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Cash flow from operating activities:      
Net loss   $ (22,626,000) $ (4,534,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation   65,000 113,000
Stock-based compensation expense   467,000 510,000
Issuance of common stock to vendor     375,000
Right-of-use asset amortization   123,000 124,000
Loss / (gain) on foreign currency transactions   336,000 (3,165,000)
Loss on investment of subsidiary $ (43,308,000) (43,308,000)  
Loss on the write-off of bad debts 45,648,000 45,648,000  
Expense for commitment shares issued upon signing the equity line of credit (ELOC)   11,874,000  
Change in fair value of derivative liabilities   3,391,000  
Change in fair value of convertible notes receivable 287,000 287,000  
Debt discount amortization   283,000  
Loss on the extinguishment of debt   371,000  
Transactions costs allocable to notes payable and equity line of credit (ELOC) 64,000 131,000  
Change in operating assets and liabilities:      
Research and development tax credit receivable     (259,000)
Prepaid expenses and other assets   (120,000) (523,000)
Accounts payable and accrued expenses   (258,000) 1,154,000
Lease liabilities   (57,000) (88,000)
Other current liabilities     172,000
Net cash used in operating activities   (3,393,000) (6,121,000)
Cash flows from investing activities:      
Payment for convertible notes receivable   (6,500,000)  
Deconsolidation of subsidiary   (852,000)  
Net cash used by investing activities   (7,352,000)  
Cash flow from financing activities:      
Payment for legal expenses related to extinguishment of debt   (10,000)  
Gross proceeds received related to note payable   2,625,000  
Payment for legal expense related to notes payable   (50,000)  
Principal payment for the settlement of note payable   (1,100,000)  
Payment for a release of claims related to notes payable   (300,000)  
Principal payment on the financing of the director and officer insurance policy   (112,000)  
Proceeds received for exercise of common stock warrants   37,000  
Net cash provided by financing activities   13,152,000  
Effect of exchange rate changes on cash   908,000 132,000
Net change in cash   3,315,000 (5,989,000)
Cash, beginning of period   374,000 7,141,000
Cash, end of period $ 3,689,000 3,689,000 1,152,000
Supplemental disclosure of cash and non-cash investing and financing activities      
Right-of-use asset and lease liability additions     $ 653,000
Initial classification of fair value of derivative liability   1,460,000  
Debt discount related to notes payable   1,125,000  
Conversion of debt to preferred stock and warrants   7,862,000  
Financing of directors' and officers' liability insurance with debt   112,000  
Private placement      
Cash flow from financing activities:      
Gross proceeds received   8,630,000  
Payments for financing expense   (1,104,000)  
Common stock and warrants purchase agreement      
Cash flow from financing activities:      
Gross proceeds received   681,000  
Payments for financing expense   (127,000)  
March 2026 Registered Direct Offering      
Cash flow from financing activities:      
Gross proceeds received   2,617,000  
Payments for financing expense   (189,000)  
Equity line of credit      
Cash flow from financing activities:      
Payments for financing expense   (17,000)  
Proceeds received related to equity line of credit (ELOC)   $ 1,571,000